Clinical trials

Completed

A 24 week phase Ib/II, multicenter, randomized, double-masked, vehicle controlled, parallel group, dose ranging study with a 24 week follow-up period to evaluate the safety and potential efficacy of two doses (60 and 180 µg/ml) of recombinant human nerve growth factor (rhNGF) eye drops solution versus vehicle in patients with typical retinitis pigmentosa (RP).

LUMOS – NGF0113

What is the purpose of this study?

Evaluate the safety and explore the biological effects of different dosages of rhNGF

Trial overview

Condition

Typical Retinitis Pigmentosa

Study Identifiers

NCT02110225

Study type

Interventional
Randomized
Vehicle controlled

Intervention

Drug: rhNGF 60 µg/ml eye drops solution
Drug: rhNGF 180 µg/ml eye drops solution
Drug: Placebo

Phase

Ib/II

Start date

Jan 2014

End Date

Nov2015

Enrollment Goal

50

Going deep into the trial

Eligibility/Recruitment

Age

≥18 years old

Gender

Accepts healthy volunteers

Key Criteria

close

Inclusion

close

Exclusion

close

Important Notes

Some information about patients involvement

Study participation will last approximately 48 weeks and will include up to 8 visits to the study center.

Desired Outcomes

close

Primary Outcomes

close

Secondary Outcomes

Find your nearest centre:

Loading...

loading...